Clinical trials: Recurrent Glioblastoma Multiforme
Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal.
- Conditions
- Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Relapsed Cancer, Recurrent Tumor
- Trial name
- NCT07416188
- Testing
- LMP744, Conventional Surgery or Biopsy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients.
- Conditions
- Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
- Trial name
- NCT03423628
- Testing
- Radiation Therapy, AZD1390
- Where
- 11 sites in United States, Japan and 1 more
- Volunteers
- 159 people
- Sponsor
- AstraZeneca
Recurrent Glioma (Glioblastoma Multiforme)
GLAD-KE GLioma Biomarker and Safety Assessment During Dietary Ketone Elevation Subtitle: A Surgical Biomarker Discovery Study of Ketogenic Therapy in Recurrent Glioma
This study is being done to see if a Ketogenic Diet (KD) or short-term Ketone supplement (KS) is feasible and safe for patients with recurrent Glioma who are undergoing a clinically indicated surgery.
- Trial name
- GLAD-KE (NCT07852975)
- Testing
- Arm 1 will use Ketone supplement 80 gm daily, Arm 2 will follow Ketogenic Diet 7 days leading up to the clinically indicated surgery.
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma Multiforme, Recurrent Glioblastoma
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
- Trial name
- FRONTIER (NCT05303467)
- Testing
- TheraSphere GBM
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Boston Scientific Corporation
Advanced Solid Tumors, Solid Tumor
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors
- Conditions
- Advanced Solid Tumors, Solid Tumor, Solid Carcinoma, Solid Tumor, Adult
- Trial name
- NCT02974738
- Testing
- Belzutifan
- Volunteers
- 120 people
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Glioblastoma, Recurrent Glioblastoma
Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer [18F]Fluciclovine and 18F-FDG PET. To compare uptake measures of 18F-Fluciclovine and 18F-FDG and MRI quantification of glutamate and lactate…
- Conditions
- Glioblastoma, Recurrent Glioblastoma, Glioblastoma Multiforme of Brain
- Trial name
- GBM (NCT06613841)
- Testing
- Fluciclovine F18
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Neoplasms, Brain, Glioblastoma Multiforme
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor.
- Conditions
- Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms
- Trial name
- NCT03911388
- Testing
- G207
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Glioblastoma Multiforme(GBM)
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
The goal of this clinical trial is to evaluate the safety and efficacy of JL15003 Injection in subjects with recurrent glioblastoma (rGMB).
- Trial name
- NCT07501559
- Testing
- JL15003Injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
Recurrent Glioblastoma Multiforme(GBM)
A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
The current design provides a window to analyze the impact of the ACT001+Pembrolizumab combination on the tumor microenvironment and disease outcomes.
- Trial name
- NCT05053880
- Testing
- ACT001, ACT001 + Pembrolizumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Accendatech USA Inc.
Recurrent Glioblastoma, Glioblastoma Multiforme
Sonodynamic Therapy in Patients With Recurrent GBM
Patients diagnosed with glioblastoma (GBM) are faced with limited treatment options. This pilot study will evaluate the safety and feasibility of combining an investigational drug called 5-ALA with neuronavigation-guided…
- Conditions
- Recurrent Glioblastoma, Glioblastoma Multiforme, GBM
- Trial name
- GBM 001 (NCT06039709)
- Testing
- 5-ALA and Low-Intensity Focused Ultrasound (SDT)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Shayan Moosa, MD
Glioblastoma Multiforme, Recurrent Glioma
Dietary Cysteine and Methionine Deprivation (CMD) in Glioma Patients
This pilot study looks at how certain diet changes affect the body in patients with recurrent brain tumors (glioma) who are planning to have standard treatment like radiation or surgery.
- Trial name
- NCT07553520
- Testing
- Normal diet, Cysteine/methionine deprivation (CMD) diet for 2 days, Cysteine/methionine deprivation (CMD) diet for 4 days
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Glioblastoma, Gliosarcoma
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
Paclitaxel is among the most active agents against glioblastoma in preclinical models. However, its clinical use has been hampered by the blood-brain barrier (BBB).
- Conditions
- Glioblastoma, Gliosarcoma, GBM, Glioblastoma Multiforme
- Trial name
- SC9/ABX (NCT04528680)
- Testing
- Sonication for opening of blood-brain barrier, Chemotherapy, albumin-bound paclitaxel, Chemotherapy, carboplatin
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Northwestern University
Glioblastoma Multiforme, Glioblastoma
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
This will be a prospective, randomized, standard of care (SoC) controlled, parallel, open-label, multicenter pivotal study to investigate the efficacy and safety of Bevacizumab (BEV) in combination with or without microbubble…
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioblastoma Multiforme, Adult, Glioma
- Trial name
- NCT06496971
- Testing
- Bevacizumab, Microbubble, Low-Intensity Focused Ultrasound
- Where
- 2 sites in Taiwan
- Volunteers
- 32 people
- Sponsor
- NaviFUS Corporation
Recurrent Glioblastoma Multiforme(GBM)
A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma
This is a single-arm, open-label, single-dose study consisting of a dose-escalation phase followed by a dose-expansion phase. Four dose levels are planned.
- Trial name
- JL15003 (NCT07497373)
- Testing
- JL15003 Injection
- Where
- 3 sites in China
- Volunteers
- 17 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
Glioblastoma, Melanoma Stage IV
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors.
- Conditions
- Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
- Trial name
- NCT04478279
- Testing
- ST101, Temozolomide, Radiation
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 125 people
- Sponsor
- Sapience Therapeutics
Recurrent Malignant Glioma, Glioblastoma Multiforme of Brain
Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
The purpose of this study is to determine how safe and how well-tolerated the experimental study drug, C134 is when re-administered into the brain where the tumor is located.
- Conditions
- Recurrent Malignant Glioma, Glioblastoma Multiforme of Brain, Gliosarcoma of Brain, Anaplastic Astrocytoma of Brain
- Trial name
- NCT06193174
- Testing
- C134 Re-Administration
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
To determine the safety and tolerability of the maximum dose for laboratory engineered Herpes Simplex Virus-1 in patients who would not be eligible for surgical resection of recurrent glioma To determine the safety and…
- Conditions
- Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma or Gliosarcoma
- Trial name
- M032-HSV-1 (NCT02062827)
- Testing
- M032 (NSC 733972)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Alabama at Birmingham
Recurrent Glioblastoma Multiforme
Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. The treatment comprises maximal safe resection followed by radiotherapy and chemotherapy.
- Trial name
- GBM Hypo RT (NCT01464177)
- Testing
- Stereotactic hypofractionated RT 5x5Gy, Stereotactic hypofractionated RT 5x7Gy
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Andre Tsin Chih Chen
Recurrent Glioblastoma Multiforme (GBM)
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
A phase I study to evaluate the safety, tolerance and pharmacokinetics of SNC109 in patients with rGBM
- Trial name
- NCT06616727
- Testing
- SNC109
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
Glioblastoma Multiforme, Adult, Recurrent Glioblastoma
Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin
The goal of this Phase 0 trial is to study if pre-operative oral pitavastatin administration reaches the tumour in patients with primary or a recurrent glioblastoma.
- Trial name
- ReDiReCCT-Pita (NCT05977738)
- Testing
- Pitavastatin calcium
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- C.Dirven